BioNTech SE

BioNTech SE is a German multinational biotechnology company headquartered in Mainz, Germany. Its core business revolves around the development of immunotherapies and vaccines, primarily for cancer and infectious diseases. The company's mission is to translate science into survival by harnessing the potential of the human immune system to improve global health through innovative immunotherapies and vaccines.

BioNTech leverages a broad array of computational discovery and therapeutic platforms, including mRNA-based therapies, engineered cell therapies, antibodies, and small molecule immunomodulators. Its key product, developed in partnership with Pfizer, is Comirnaty, the first approved mRNA-based COVID-19 vaccine. Beyond infectious diseases, BioNTech maintains a significant pipeline in oncology, featuring individualized and off-the-shelf mRNA-based therapies, chimeric antigen receptor T cells (CAR-T), bi-specific checkpoint immuno-modulators, and targeted cancer antibodies.

In a notable development, co-founders Prof. Ugur Sahin (CEO) and Prof. Özlem Türeci (CMO) announced plans to transition by the end of 2026 to lead a new independent mRNA company, with BioNTech contributing related rights and technologies. This news impacted BioNTech's share price. The company is actively expanding its oncology pipeline, with 15 Phase 3 oncology trials expected by the end of 2026 and multiple late-stage data readouts anticipated. BioNTech also acquired British AI technology company InstaDeep in 2023 to enhance its AI-driven drug development capabilities. The company aims to become a multi-product entity by 2030, navigating potential challenges such as US pharmaceutical tariffs.